LivaNova PLC (NASDAQ:LIVN) Receives $69.83 Average Target Price from Brokerages

Shares of LivaNova PLC (NASDAQ:LIVN) have received a consensus recommendation of “Buy” from the seven brokerages that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $69.83.

Several analysts recently issued reports on the company. Needham & Company LLC upped their target price on LivaNova from $72.00 to $75.00 and gave the stock a “buy” rating in a report on Wednesday, July 31st. Robert W. Baird raised LivaNova from a “neutral” rating to an “outperform” rating and raised their price target for the company from $55.00 to $66.00 in a report on Tuesday, September 17th. The Goldman Sachs Group initiated coverage on shares of LivaNova in a report on Friday, October 4th. They issued a “buy” rating and a $65.00 price objective for the company. Stifel Nicolaus upped their price target on shares of LivaNova from $70.00 to $72.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Finally, Baird R W raised shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 17th.

LivaNova Price Performance

NASDAQ LIVN opened at $53.19 on Monday. The firm’s 50 day moving average is $49.39 and its 200-day moving average is $53.25. The company has a quick ratio of 2.94, a current ratio of 3.45 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $2.88 billion, a PE ratio of -88.65 and a beta of 1.00. LivaNova has a 12-month low of $42.75 and a 12-month high of $64.47.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings results on Wednesday, July 31st. The company reported $0.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.66 by $0.15. LivaNova had a negative net margin of 1.37% and a positive return on equity of 13.77%. The firm had revenue of $318.60 million for the quarter, compared to analyst estimates of $305.05 million. Equities research analysts anticipate that LivaNova will post 2.58 earnings per share for the current fiscal year.

Hedge Funds Weigh In On LivaNova

Several institutional investors have recently added to or reduced their stakes in LIVN. Hexagon Capital Partners LLC boosted its position in LivaNova by 117.8% during the second quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock worth $37,000 after purchasing an additional 370 shares during the period. Fifth Third Bancorp boosted its stake in LivaNova by 97.1% during the second quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock valued at $37,000 after buying an additional 332 shares during the period. Lazard Asset Management LLC bought a new position in shares of LivaNova in the first quarter worth approximately $84,000. Canada Pension Plan Investment Board purchased a new stake in shares of LivaNova during the 2nd quarter valued at $88,000. Finally, Acadian Asset Management LLC bought a new stake in LivaNova during the first quarter worth about $94,000. Institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.